IL-17 levels in serum were significantly higher in NSCLC patients (394.17 ± 38.29 pg/mL) than in healthy controls (147.27 ± 20.66 pg/mL, P < 0.0001) (Figure 1(b)). This evidence concerns the gene IL17A and non-small cell lung carcinoma.